<?xml version="1.0"?>
<root>
  <patent>
    <patent_id>20150335730</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>November 26, 2015</report_date>
    <title>RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS</title>
    <abstract>The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=1&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20150320858</patent_id>
    <inventor>Morein; Bror; et al.</inventor>
    <report_date>November 12, 2015</report_date>
    <title>QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF</title>
    <abstract>Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=2&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20150307849</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>October 29, 2015</report_date>
    <title>HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS</title>
    <abstract>This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=3&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20150306207</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>October 29, 2015</report_date>
    <title>RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS</title>
    <abstract>The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=4&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20150306206</patent_id>
    <inventor>ROBINSON; Robin A.; et al.</inventor>
    <report_date>October 29, 2015</report_date>
    <title>FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS)</title>
    <abstract>Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=5&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20150266930</patent_id>
    <inventor>PUSHKO; Peter; et al.</inventor>
    <report_date>September 24, 2015</report_date>
    <title>MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE</title>
    <abstract>The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=6&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20150265698</patent_id>
    <inventor>PUSHKO; Peter; et al.</inventor>
    <report_date>September 24, 2015</report_date>
    <title>MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE</title>
    <abstract>The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=7&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20150209425</patent_id>
    <inventor>MOREIN; BROR; et al.</inventor>
    <report_date>July 30, 2015</report_date>
    <title>ISCOM PREPARATION AND USE THEREOF</title>
    <abstract>The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja Saponaria Molina. The complexes may be iscom complexes or iscom matrix complexes. The invention also pertains to the use of such a mixture for the preparation of an immunomodulating pharmaceutical, and adjuvant, formulations for immunization, e.g. for production of monoclonal antibodies, and a vaccine. Kits of parts comprising at least two parts, wherein each part comprises one iscom complex or one iscom matrix complex according to the invention are also embraced.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=8&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20140335049</patent_id>
    <inventor>Morein; Bror; et al.</inventor>
    <report_date>November 13, 2014</report_date>
    <title>QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF</title>
    <abstract>Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=9&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20140294879</patent_id>
    <inventor>PUSHKO; Peter; et al.</inventor>
    <report_date>October 2, 2014</report_date>
    <title>MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE</title>
    <abstract>The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=10&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20140271697</patent_id>
    <inventor>MASSARE; Michael J.</inventor>
    <report_date>September 18, 2014</report_date>
    <title>ENHANCED EXPRESSION OF PICORNAVIRUS PROTEINS</title>
    <abstract>The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=11&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20140234372</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>August 21, 2014</report_date>
    <title>NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL MATRIX OR CORE PROTEIN</title>
    <abstract>The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=12&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20140227309</patent_id>
    <inventor>SMITH; Gale E.; et al.</inventor>
    <report_date>August 14, 2014</report_date>
    <title>COMBINATION VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS AND INFLUENZA</title>
    <abstract>The present disclosure is directed to compositions and methods for raising immune responses against influenza and respiratory synctial virus by administering combination immunogenic composition against both viruses at the same time. The combination compositions contain an RSV component and one, two, three, four, or more influenza components. The combination compositions provide a greater immune response than that obtained by separately administering the RSV and influenza components.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=13&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20140193447</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>July 10, 2014</report_date>
    <title>FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS)</title>
    <abstract>The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=14&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20140178419</patent_id>
    <inventor>Smith; Gale; et al.</inventor>
    <report_date>June 26, 2014</report_date>
    <title>RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPS)</title>
    <abstract>The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=15&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20140120131</patent_id>
    <inventor>Morein; Bror; et al.</inventor>
    <report_date>May 1, 2014</report_date>
    <title>COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS</title>
    <abstract>Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=16&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20130295135</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>November 7, 2013</report_date>
    <title>FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs)</title>
    <abstract>The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=17&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20130177587</patent_id>
    <inventor>ROBINSON; Robin A.; et al.</inventor>
    <report_date>July 11, 2013</report_date>
    <title>FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS)</title>
    <abstract>Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=18&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20130039938</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>February 14, 2013</report_date>
    <title>HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS</title>
    <abstract>This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=19&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20120207786</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>August 16, 2012</report_date>
    <title>FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS)</title>
    <abstract>The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=20&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20110245186</patent_id>
    <inventor>Smith; Gale; et al.</inventor>
    <report_date>October 6, 2011</report_date>
    <title>RECOMBINANT E-SELECTIN MADE IN INSECT CELLS</title>
    <abstract>The inventive features include recombinant mammalian E-selectin peptides, nucleic acids encoding said peptides, vectors and cells having these nucleic acids, and methods of making the peptides. Further inventive features include methods of treating diseases and conditions associated with inflammation using recombinant mammalian E-selectin peptides to induce mucosal tolerance to E-selectin.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=21&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20100226932</patent_id>
    <inventor>Smith; Gail; et al.</inventor>
    <report_date>September 9, 2010</report_date>
    <title>Adjuvant and Vaccine Compositions</title>
    <abstract>Abstract Compositions comprising an emulsion and aluminum salt nano-/micro-particles surface stabilized with at least one surfactant are useful as immunological adjuvants. The emulsion of these compositions comprises at least one oil; at least one surfactant; a plurality of surfactant vesicles; optionally at least one sterol; and an aqueous phase. The present invention also provides vaccines comprising one or more antigens combined with the emulsion and surface stabilized aluminum salt particles of the present invention, or one or more antigens combined with non-ionic surfactant vesicles.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=22&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20100035813</patent_id>
    <inventor>SMITH; Gale; et al.</inventor>
    <report_date>February 11, 2010</report_date>
    <title>RECOMBINANT E-SELECTIN MADE IN INSECT CELLS</title>
    <abstract>The inventive features include recombinant mammalian E-selectin peptides, nucleic acids encoding said peptides, vectors and cells having these nucleic acids, and methods of making the peptides. Further inventive features include methods of treating diseases and conditions associated with inflammation using recombinant mammalian E-selectin peptides to induce mucosal tolerance to E-selectin.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=23&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20080299206</patent_id>
    <inventor>Lee; Robert; et al.</inventor>
    <report_date>December 4, 2008</report_date>
    <title>Ophthalmic preparations</title>
    <abstract>The present invention provides ophthalmic formulations containing cyclosporine, methods for preparing the formulation, and methods for using the formulation.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=24&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20080139513</patent_id>
    <inventor>Lee; Robert; et al.</inventor>
    <report_date>June 12, 2008</report_date>
    <title>TRANSDERMAL DELIVER OF ACTIVE AGENTS</title>
    <abstract>A composition for transdermal delivery of a non-traditional active agent is described. The compositions comprise: (a) a non-traditional transdermal active agent; (b) a solvent; (c) a non-miscible liquid; (d) a stabilizer; and (e) water, wherein the composition is formulated into an emulsion.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=25&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20070264349</patent_id>
    <inventor>Lee; Robert; et al.</inventor>
    <report_date>November 15, 2007</report_date>
    <title>Nano-structured compositions and methods of making and using the same</title>
    <abstract>The present invention provides a new tri-phasic method for making nanoparticles of poorly soluble active pharmaceutical ingredients.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=26&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20070244043</patent_id>
    <inventor>Smith; Gale; et al.</inventor>
    <report_date>October 18, 2007</report_date>
    <title>Recombinant E-selectin made in insect cells</title>
    <abstract>The inventive features include recombinant mammalian E-selectin peptides, nucleic acids encoding said peptides, vectors and cells having these nucleic acids, and methods of making the peptides. Further inventive features include methods of treating diseases and conditions associated with inflammation using recombinant mammalian E-selectin peptides to induce mucosal tolerance to E-selectin.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=27&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20060263804</patent_id>
    <inventor>Robinson; Robin A.; et al.</inventor>
    <report_date>November 23, 2006</report_date>
    <title>Functional influenza virus-like particles (VLPs)</title>
    <abstract>Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=28&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20060251722</patent_id>
    <inventor>Bandak; Stephen I.; et al.</inventor>
    <report_date>November 9, 2006</report_date>
    <title>Multi-component vitamin and mineral supplement for the optimal absorption of components</title>
    <abstract>The present invention relates to compositions and methods for administration of vitamin-mineral supplements, including those given to women prenatally. A multi-component vitamin delivery system is described comprising a first layer able to release a first set of components at a first location in the gastrointestinal tract, the first set of components includes iron in a form absorbable at the first location and a second layer able to release a second set of components at a second location in the gastrointestinal tract, the second location being further downstream in the gastrointestinal tract than the first location. The second set of components includes at least one material that reduces or inhibits the absorption of iron or whose absorption is inhibited by iron. Components are incorporated into the different layers of the delivery system to minimize the potential for interactions that may impair absorption and maximize conditions for optimal absorption.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=29&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20050118201</patent_id>
    <inventor>Wright, D. Craig; et al.</inventor>
    <report_date>June 2, 2005</report_date>
    <title>Mycobacterial vaccine</title>
    <abstract>Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome.RTM. adjuvant, as well as methods for using such compositions.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=30&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20050118191</patent_id>
    <inventor>Robinson, Robin A.; et al.</inventor>
    <report_date>June 2, 2005</report_date>
    <title>Optimization of gene sequences of chimeric virus-like particles for expression in insect cells</title>
    <abstract>Chimeric virus-like particles that exhibit conformational antigenic epitopes capable of eliciting neutralizing antibodies are disclosed herein. The chimeric virus-like particles of the invention comprise a recombinant viral capsid protein that encapsulates a recombinant viral protein during self-assembly into a chimeric virus-like particle, wherein the chimeric virus-like particle exhibits confirmational antigenic epitopes capable of eliciting neutralizing antibodies. Pharmaceutical compositions, vaccines, and diagnostic test kits containing the chimeric virus-particles are also provided.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=31&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20040121465</patent_id>
    <inventor>Robinson, Robin A.</inventor>
    <report_date>June 24, 2004</report_date>
    <title>Optimization of gene sequences of virus-like particles for expression in insect cells</title>
    <abstract>Codon optimized polynucleotides for optimal expression of recombinant proteins in eukaryotic cells are provided. The codon optimized polynucleotides encode a viral capsid protein that self assembles into a virus-like particle. The virus-like particle is expressed extracellularly and exhibits conformational antigenic epitopes capable of raising neutralizing antibodies. Pharmaceutical compositions, vaccines, and diagnostic test kits containing the gene products of the codon-optimized polynucleotides are also provided.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=32&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20040063188</patent_id>
    <inventor>Robinson, Robin A.; et al.</inventor>
    <report_date>April 1, 2004</report_date>
    <title>Kit for treating gastrointestinal tract</title>
    <abstract>Methods for isolation and purification or recombinant gene products are disclosed. In particular, methods for isolation and purification of extracellular and intracellular viral gene products, including virus-like particles, are disclosed herein.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=33&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
  <patent>
    <patent_id>20030228696</patent_id>
    <inventor>Robinson, Robin A.</inventor>
    <report_date>December 11, 2003</report_date>
    <title>Novel insect cell line</title>
    <abstract>An insect cell line capable of growth in serum-free media and secretion of high levels of recombinant proteins, including virus-like particles, upon infection with recombinant baculoviruses, is provided. Methods involving clonal selection processes, serum-weaning and recombinant protein secretion selection are used to create the insect lines of the invention. This cell line supports replication of baculoviruses, serves as host substrate for baculovirus plaque assays, provides a source of insect proteins, acts as a depot for cell transfection to produce recombinant baculoviruses, and express viral recombinant proteins. Extracellular and intracellular viral recombinant proteins and virus-like particles expressed from this cell line are useful as pharmaceutical compositions, vaccines, or diagnostic reagents.</abstract>
    <link>http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=34&amp;f=G&amp;l=50&amp;co1=OR&amp;d=PG01&amp;s1=Novavax.AS.&amp;s2=Novavax.AANM.&amp;OS=AN/Novavax+OR+AANM/Novavax&amp;RS=AN/Novavax+OR+AANM/Novavax</link>
  </patent>
</root>
